林海元

胆管癌（CCA）是一组异质性侵袭性恶性肿瘤，起源于胆管树内的不同部位。胆管癌（CCA）是继肝细胞癌之后第二常见的肝癌类型，占所有原发性肝脏恶性肿瘤的10-15%。在过去十年中，CCA 的发病率和死亡率都在稳步上升。本文主要就胆管癌的诊断及手术治疗进行阐述。

胆管癌；诊断；手术治疗

[1] Alvaro D, et al. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver Disease. Dig. Liver Dis. 2011;43:60–65. [2] Macias RIR, Kornek M,Rodrigues PM,et al. Diagnostic and prog-nostic biomarkers in cholangiocarcinoma. Liver Int.2019;39(suppl1):108-122. [3] Rahnemai-Azar AA,Weisbrod A, Dillhoff M, Schmidt C,Pawlik TM.Intrahepatic cholangiocarcinoma: molecular markers for diagnosis and prognosis.Surg Oncol.2017;26(2):125-137. [4] Macias RIR,Banales JM,Sangro B, et al. The search for noveldiagnostic and prognostic biomarkers in cholangiocarcinoma.Bio- chim Biophys Acta, Mol Basis Dis.2018;1864(4Pt B):1468-1477. [5] RizviS,EatonJ,YangJD,ChandrasekharaV,GoresGJ.Emergingtechnologies for the diagnosis of perihilar cholangiocarcinoma. Semin Liver Dis.2018;38(2):160-169. [6] Sirica AE, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69:1803–1815. [7] Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology. 2018;288:7–13. [8] Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J. Magn. Reson. Imaging. 2015;42:1165–1179. [9] Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–69. [10] Farha N, Dima D, Ullah F, Kamath S. Precision oncology targets in biliary tract cancer. Cancers (Basel). 2023;15(7):2105. 10.3390/cancers15072105. [11] Ohaegbulam KC, Koethe Y, Fung A, Mayo SC, Grossberg AJ, Chen EY, Sharzehi K, Kardosh A, Farsad K, Rocha FG, Thomas CR, Nabavizadeh N. The multidisciplinary management of cholangiocarcinoma. Cancer. 2023 Jan 15;129(2):184-214. [12] Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7:325–30. [13] Olthof PB, Wiggers JK, Groot Koerkamp B, Coelen RJ, Allen PJ, Besselink MG, et al. Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization. J Am Coll Surg 2017;225:387–94. [14] Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012;255:405–14. [15] Katayose Y, Rikiyama T, Motoi F, Yamamoto K, Yoshida H, Morikawa T, et al. Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study). Hepatogastroenterology 2011;58:1866–72.

点击下载PDF